AI Chronic Disease Management and Prescription Transfer Platform

📌 Background

Following the integration of prescription outflow with online medical insurance payment, the demand for chronic disease medication is high-frequency and continuous; in 2026, the application of medical AI models has accelerated, and platforms can use intelligent follow-ups and personalized medication guidance to reduce labor costs in chronic disease management. Benchmarking Ark Health's 2025 annual performance report, its full-year revenue reached 3.53 billion yuan, a year-on-year increase of 30.2%, with prescription drugs accounting for over 80% of the platform's GMV (based on listed company annual reports), indicating that 'AI + Chronic Disease' has achieved scalable revenue.

👤 Target Customers

Chronic disease patients, pharmaceutical companies, commercial insurance institutions

💰 Revenue Streams

1) Online drug sales: Earn gross margin from the purchase-sale price difference of prescription and chronic disease drugs, serving as the foundational cash flow source; 2) Pharmaceutical company services: Provide digital marketing and real-world study data services for pharmaceutical companies, settled on a project basis; 3) Insurance direct billing and consultations: Earn commissions per order from insurance direct billing orders and online consultations; 4) Chronic disease management membership: Monthly subscription fee, which is currently an opportunity item, and public figures for its exact revenue potential are not yet available.

🧮 Cost Structure

AI computing power and model fine-tuning costs, salaries for the in-house team of physicians and pharmacists, cold chain logistics, and DTP pharmacy operating costs

🛡️ Moat

Massive chronic disease medication data closed-loop, internet hospital licenses and medical insurance integration qualifications, supply chain scale bargaining power

🔑 Keys to Success

• Accuracy and compliance of AI chronic disease management models in medical scenarios
• Deep integration of prescription transfer with medical and commercial insurance payment systems
• Construction of DTP pharmacy cold chain and professional pharmaceutical service networks

⚠️ Risks

• Changes in medical insurance regulatory policies restricting the scope of prescription outflow
• Medication safety liability disputes caused by misleading suggestions from AI large models

🏢 Cases

• 方舟健客
• 阿里健康
• 圆心科技

📊 SWOT Analysis